Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia.
Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, Sullivan AH, Viboch EJ, Patel T, Ibrahimova N, Warren SE, Arruda A, Liang Y, Smith TH, Foulds GA, Bailey MD, Gowen-MacDonald J, Muth J, Schmitz M, Cesano A, Pockley AG, Valk PJM, Löwenberg B, Bornhäuser M, Tasian SK, Rettig MP, Davidson-Moncada JK, DiPersio JF, Rutella S. Vadakekolathu J, et al. Among authors: tasian sk. Sci Transl Med. 2020 Jun 3;12(546):eaaz0463. doi: 10.1126/scitranslmed.aaz0463. Sci Transl Med. 2020. PMID: 32493790 Free PMC article.
Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.
Ang Z, Paruzzo L, Hayer KE, Schmidt C, Torres Diz M, Xu F, Zankharia U, Zhang Y, Soldan S, Zheng S, Falkenstein CD, Loftus JP, Yang SY, Asnani M, King Sainos P, Pillai V, Chong E, Li MM, Tasian SK, Barash Y, Lieberman PM, Ruella M, Schuster SJ, Thomas-Tikhonenko A. Ang Z, et al. Among authors: tasian sk. bioRxiv [Preprint]. 2023 Aug 16:2023.02.19.529123. doi: 10.1101/2023.02.19.529123. bioRxiv. 2023. PMID: 37645778 Free PMC article. Updated. Preprint.
Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.
Tian Z, Shi C, Yang G, Allen JK, Shi Q, Al-Shami A, Olson JW, Smith MG, Chang Q, Kaur J, You J, Lofton TE, Gonzalez MA, Zhang Q, Zha D, Tasian SK, Jain N, Konopleva MY, Heffernan T, Molldrem JJ. Tian Z, et al. Among authors: tasian sk. Leukemia. 2023 Oct;37(10):2006-2016. doi: 10.1038/s41375-023-02010-y. Epub 2023 Aug 26. Leukemia. 2023. PMID: 37634013 Free PMC article.
Opportunities for immunotherapy in childhood acute myeloid leukemia.
Lamble AJ, Tasian SK. Lamble AJ, et al. Among authors: tasian sk. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):218-225. doi: 10.1182/hematology.2019000357. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808843 Free PMC article. Review.
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H, Yang L, Chukinas JA, Shah N, Tarun S, Pouzolles M, Chien CD, Niswander LM, Welch AR, Taylor N, Tasian SK, Fry TJ. Qin H, et al. Among authors: tasian sk. J Immunother Cancer. 2021 Sep;9(9):e003149. doi: 10.1136/jitc-2021-003149. J Immunother Cancer. 2021. PMID: 34531250 Free PMC article.
99 results